Literature DB >> 583048

Metabolic clearance and production rates of prolactin in man.

D S Cooper, E C Ridgway, B Kliman, R N Kjellberg, F Maloof.   

Abstract

Metabolic clearance rates (MCR) and production rates (PR) of prolactin (PRL) have been determined by the constant infusion to equilibrium technique in 11 normal subjects, 6 patients with hyperthyroidism, 4 patients with hypothyroidism, and 9 patients with hyperprolactinemia. PRL MCR was also determined tin four patients during dopamine infusion. Mean PRL MCR was 46 +/- 1 ml/min per m2 in women and 44 +/- 3 ml/min per m2 in men, and was significantly correlated with body mass (r = 0.84, P less than 0.001). In contrast with controls, PRL MCR was higher in hyperthyroidism (MCR = 52 +/- 8 ml/min per m2, P less than 0.05), was slightly lower in hypothyroidism (MCR = 38 +/- 10 ml/min per m2, P = NS), and was significantly correlated with serum thyroxine (r = 0.46, P less than 0.02). PRL MCR was lower than controls in hyperprolactinemia (MCR = 40 +/- 5 ml/min per m2, P less than 0.01) and was inversely correlated with serum PRL (r = -0.72, P less than 0.001). PRL MCR was not significantly changed by dopamine infusion. Mean PRL PR for women and men was 211 +/- 74 and 187 +/- 44 micrograms/d per m2, respectively (P = NS). In hyperthyroidism the PRL PR was elevated (PR = 335 +/- 68 micrograms/d per m2, P less than 0.02), but in hypothyroidism the increase (PR = 233 +/- 159 micrograms/d per m2) was not significant. In hyperprolactinemia the PRL PR was extremely high (PR = 31,000 +/- 29,000 micrograms/d per m2). Dopamine infusion decreased RPL PR from 270 to 66 micrograms/d per m2 indicating that its effect was on pituitary PRL secretion and not PRL metabolism. To evaluate possible circulating PRL heterogeneity that might arise during infusion, gel filtration of infusate and serum obtained during the MCR procedure was performed. Labeled monomeric PRL (peak III, Kav (partition coefficient) = 0.4) was partially converted to two larger forms (peaks I and II) in vivo. Peak I (Kav = 0) was 30--40% immunoprecipitable, although peak II (Kav = 0.2) was not immunoprecipitable. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of peak I resulted in greater than or equal to 90% conversion to peak III and restoration of full immunoactivity. Thus, peak I is a noncovalently linked aggregate that is partially immunoactive, and therefore able to alter MCR determinations. These studies demonstrate the impact of hormone heterogeneity on MCR estimations and suggest that gel filtration of immunoprecipitable material be an integral part of future MCR measurements.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 583048      PMCID: PMC371321          DOI: 10.1172/JCI109629

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  Spectrum of pituitary alterations with mild and severe thyroid impairment.

Authors:  S T Bigos; E C Ridgway; I A Kourides; F Maloof
Journal:  J Clin Endocrinol Metab       Date:  1978-02       Impact factor: 5.958

2.  Regulation of pituitary receptors for thyrotropin-releasing hormone by thyroid hormones.

Authors:  M H Perrone; P M Hinkle
Journal:  J Biol Chem       Date:  1978-07-25       Impact factor: 5.157

3.  Specific binding of iodinated growth hormone to rat liver in vivo.

Authors:  D Turyn; J M Dellacha
Journal:  Endocrinology       Date:  1978-10       Impact factor: 4.736

4.  Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of "Big" prolactin in a radioreceptor assay and evidence for its secretion.

Authors:  P E Garnier; M L Aubert; S L Kaplan; M M Grumbach
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

5.  Size heterogeneity of human prolactin in CSF and serum: experimental conditions that alter gel filtration patterns.

Authors:  K A Kiefer; W B Malarkey
Journal:  J Clin Endocrinol Metab       Date:  1978-01       Impact factor: 5.958

6.  Serum prolactin levels in untreated primary hypothyroidism.

Authors:  K S Honbo; A J van Herle; K A Kellett
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

7.  Letter: Radioimmunoassay of plasma--prolactin.

Authors:  P J Wood; M M Shahwan; V Marks
Journal:  Lancet       Date:  1975-11-22       Impact factor: 79.321

8.  Estrogen control of prolactin synthesis in vitro.

Authors:  M E Lieberman; R A Maurer; J Gorski
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

9.  Heterogeneous human prolactin from a giant pituitary tumor in a patient with panhypopituitarism.

Authors:  V S Fang; S Refetoff
Journal:  J Clin Endocrinol Metab       Date:  1978-10       Impact factor: 5.958

10.  [125I]hGH metabolism in acromegaly: effects of chronic treatment with 2-Br-alpha-ergocryptine.

Authors:  F Maneschi; R Navalesi; A Pilo; A Paci
Journal:  J Clin Endocrinol Metab       Date:  1978-07       Impact factor: 5.958

View more
  12 in total

1.  Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.

Authors:  Guangli Ma; Lena E Friberg; Gunilla Movin-Osswald; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

2.  Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922.

Authors:  P Francheteau; J L Steimer; C Dubray; D Lavene
Journal:  J Pharmacokinet Biopharm       Date:  1991-06

3.  A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist.

Authors:  G Acton; C Broom
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

4.  Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model.

Authors:  J Grevel; J Brownell; J L Steimer; R C Gaillard; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

Review 5.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

6.  Immunoreactive prolactin like material in the urine of women.

Authors:  V Ghuysen; J R Van Cauwenberge; A Reuter; Y Vrindts-Gevaert; P Franchimont
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

7.  Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.

Authors:  M Follenius; K Spiegel; C Gronfier; J Saini; G Brandenberger
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

8.  Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.

Authors:  Klas J Petersson; An M Vermeulen; Lena E Friberg
Journal:  AAPS J       Date:  2013-02-08       Impact factor: 4.009

9.  Vasoactive intestinal peptide-induced prolactin release in hypothyroid patients.

Authors:  R Valcavi; M Zini; C Dieguez; I Portioli
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

10.  Biphasic effects of moderate drinking on prolactin during lactation.

Authors:  Julie A Mennella; Marta Yanina Pepino
Journal:  Alcohol Clin Exp Res       Date:  2008-08-18       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.